# RC48-C009 (NCT03809013)

> A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer

No report yet. It can be ordered.

- Drugs tested: disitamab vedotin
- Indication: HER2-overexpressing locally advanced or metastatic urothelial carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03809013
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: RemeGen Co., Ltd.
- Conditions: Urothelial Carcinoma
- Interventions: RC48-ADC
- Enrollment: 64
- Primary outcome: Objective Response Rate （ORR）as assessed by the Independent Review Committee

## Indexed commentary on RC48-C009 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=rc48-c009-nct03809013